Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab

fiercebiotechJanuary 03, 2019

Tag: ASH18 , J&J , blood cancer , Argenyx

PharmaSources Customer Service